PPT-Switch to DOR-TDF-3TC vs. Continued Baseline Regimen

DRIVE SHIFT Switch to DoravirineTDF3TC versus Continued Baseline Regimen DRIVE SHIFT Design Source Johnson M et al J Acquir Immun Defic Syndr 20198146372 Design Openlabel noninferiority trial in adults with suppressed HIV RNA while taking 2 NRTIs plus anchor drug randomized 21 to immediately switch to fixeddose . Our aim is to promote active particip ation in your care and treatment by providing information and education Questions about individual health concerns or specific treatment options should be discussed with your physician 2011 The Regents of the Un monotherapy. MONOI. MONET. PROTEA. DRV600. Design. Objective. Non inferiority in the proportion of patients with HIV-1 RNA < 50 c/. mL. at W48 (ITT analysis, missing/discontinuation/switch= failure, snapshot algorithm. M Harris, . S Guillemi. , K Chan, B Yip. ,. . M Hull, V Dias Lima, R Hogg, J . Montaner. Abstract #: WEAB0202. Organ Dysfunction in HIV: It's . Complicated. Wednesday, 3 July 2013 14:30-16:. 00. Session . STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . Instructor Name:. . (Your Name). 9. CHAPTER. Learning Objectives. Explain how temperature is controlled in a blend air system.. Explain how temperature is controlled in a water-valve controlled system.. X. J . Hepatology. 2015; 63: 564-72. C-SALVAGE Study: . grazoprevir. . + . elbasvir. + RBV in genotype 1 with failure to PI-based regimen. NS3 and NS5A RAVs identified by population sequencing at baseline and VF. SPARE . Study. SPARE Study: switch to DRV/r + RAL . Design. Age ≥ . 20. years. HIV+. HIV-1 RNA. < 50 c/ml > 15 weeks. On LPV/r + TDF/FTC. No prior . virologic. failure. on PI/r- or INSTI-containing regimen. Study GS-US-292-0119. E/C/F/TAF + DRV 800 mg QD. N = 89. N = 46. Baseline regimen. Design. Randomisation*. 2: 1. Open-label. Objective. Primary Endpoint: proportion with treatment success (HIV RNA < 50 c/mL) . THE SHORTER MDR-FEATURESOFTHESHORTERMDR-TBREGIMENStandardized shorter MDR-TB regimen with seven drugs anda treatment duration of9-12 monthsIndicated conditionally in MDR-TBor rifampicin-resistant-TB r Dovato. ). Last Updated: November 28, 2022. Prepared by:. Brian R. Wood, MD. David H. Spach, MD. Dolutegravir-Lamivudine. Photograph courtesy of . ViiV. INSTI. NRTI. 50 mg. 300 mg. Dolutegravir-Lamivudine. Switch to ATV/r-. containing. . regimen. ATAZIP. Switch to ATV ± r-containing . regimen. SWAN . Study. SLOAT . Study. Switch . to ATV-. containing. . regimen. ARIES . Study. INDUMA . Study. ASSURE . Canadian Study. CHEER. Montreal Study. EASIER. SWITCHMRK. SPIRAL. Switch ER. Design. Endpoints. Primary: non inferiority in the proportion of patients with treatment failure at W48* (non completer = failure, intent-to-treat analysis), lower . 1. ViiV Healthcare, Brentford, UK; . 2. Centre Hospitalier de Tourcoing, Tourcoing, France; . 3. Holdsworth House Medical Brisbane, Queensland, Australia; . 4. CHU Saint-Pierre, Brussels, Belgium; . 5. Etraswitch. . Study. : Switch PI/r to ETR. Continuation of current . PI/R . + 2 . NRTI. N = . 21. N = . 22. ETR 400 mg QD* . + 2 NRTI. Design. Randomisation. 1: 1. Open-label. Objective. Primary . Endpoint: % HIV RNA < 50 c/mL, on-treatment and ITT, M=F.